Search Results

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”).

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announced that it had won an award from the U.S. Defense Innovation Unit, a division of the U.S. Department of Defense, for ‘Exhaled Breath Diagnostics’.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), is pleased to announce a Memorandum of Understanding (“MOU”) between SQI and Owlstone Medical to work together on the discovery, development and commercialization of breath-based biomarkers relating to invasive aspergillus lung infection and lung transplant rejection.

Medical robotics innovatorNoah Medical today announced the final results from its FRONTIER Study, the platform’s first-in-human clinical trial testing the “Tool-in-Lesion” accuracy of its Galaxy System™, are now available for review in the Official Journal of the Asian Pacific Society of Respirology.

Radon Medical Imaging, a leading medical imaging equipment maintenance and repair services company, announced it was selected as the Medical Imaging Asset Management firm for several Vandalia Health facilities.

Tri-Tech Forensics, Inc., a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical, a globally renowned provider of innovative medical devices and trauma care solutions including tourniquets, hemostatics, splints, pelvic binders, and intraosseous access systems.

GT Medical Technologies, Inc. today announced two significant additions to its leadership team: Tom Moore as Chief Commercial Officer and Sandeep Yadav as Chief Financial Officer.

Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet’s Disease.

Avanos Medical, Inc. (NYSE: AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors.